Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
01 nov. 2024 09h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued...
Qualigen Therapeutics, Inc. Announces management changes.
26 sept. 2024 17h10 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors...
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
20 sept. 2024 09h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq...
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
06 sept. 2024 16h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058...
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering
05 sept. 2024 09h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock,...
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
30 mai 2024 16h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), announced today that on May 23, 2024, it received written notice (the...
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
10 avr. 2024 08h00 HE
|
Qualigen Therapeutics, Inc.
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN)...
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
09 avr. 2024 08h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience...
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
14 nov. 2023 16h30 HE
|
Qualigen Therapeutics, Inc.
Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates...
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
07 nov. 2023 08h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers...